XML 41 R29.htm IDEA: XBRL DOCUMENT
v3.7.0.1

Supplemental Data | 6 Months Ended
--- | ---
Jun. 30, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract] |
Supplemental data | Supplemental data The following information is presented as supplemental data as required by the indentures governing the Company’s senior notes. Condensed Consolidating Statements of Income
| Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For The Six Months Ended June 30, 2017 |  |  |
Patient service operating revenues | $ | 5,283,845 |  |  | $ | 273,017 |  |  | $ | — |  |  | $ | 5,010,828 |
Less: Provision for uncollectible accounts | (228,468 | ) |  | (7,351 | ) |  | — |  |  | (221,117 | )
Net patient service operating revenues | 5,055,377 |  |  | 265,666 |  |  | — |  |  | 4,789,711 |
Capitated revenues | 1,940,114 |  |  | 785,139 |  |  | — |  |  | 1,154,975 |
Other revenues | 579,269 |  |  | 19,596 |  |  | — |  |  | 559,673 |
Total net operating revenues | 7,574,760 |  |  | 1,070,401 |  |  | — |  |  | 6,504,359 |
Operating expenses | 6,308,208 |  |  | 1,032,529 |  |  | (232 | ) |  | 5,275,911 |
Operating income | 1,266,552 |  |  | 37,872 |  |  | 232 |  |  | 1,228,448 |
Debt expense, including refinancing charges | (212,391 | ) |  | (3,323 | ) |  | — |  |  | (209,068 | )
Other income | 9,496 |  |  | 151 |  |  | — |  |  | 9,345 |
Income tax expense | 401,747 |  |  | 32,700 |  |  | 93 |  |  | 368,954 |
Net income | 661,910 |  |  | 2,000 |  |  | 139 |  |  | 659,771 |
Less: Net income attributable to noncontrolling interests | (87,212 | ) |  | — |  |  | — |  |  | (87,212 | )
Net income attributable to DaVita Inc. | $ | 574,698 |  |  | $ | 2,000 |  |  | $ | 139 |  |  | $ | 572,559 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Comprehensive Income
| Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For The Six Months Ended June 30, 2017 |  |  |
Net income | $ | 661,910 |  |  | $ | 2,000 |  |  | $ | 139 |  |  | $ | 659,771 |
Other comprehensive income | 62,333 |  |  | — |  |  | — |  |  | 62,333 |
Total comprehensive income | 724,243 |  |  | 2,000 |  |  | 139 |  |  | 722,104 |
Less: Comprehensive income attributable to the noncontrolling interests | (87,210 | ) |  | — |  |  | — |  |  | (87,210 | )
Comprehensive income attributable to DaVita Inc. | $ | 637,033 |  |  | $ | 2,000 |  |  | $ | 139 |  |  | $ | 634,894 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Balance Sheets
| Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
As of June 30, 2017 |  |  |
Cash and cash equivalents | $ | 711,997 |  |  | $ | 107,232 |  |  | $ | — |  |  | $ | 604,765 |
Accounts receivable, net | 2,053,812 |  |  | 213,804 |  |  | — |  |  | 1,840,008 |
Other current assets | 1,257,959 |  |  | 13,679 |  |  | — |  |  | 1,244,280 |
Total current assets | 4,023,768 |  |  | 334,715 |  |  | — |  |  | 3,689,053 |
Property and equipment, net | 3,248,030 |  |  | 3,368 |  |  | — |  |  | 3,244,662 |
Amortizable intangibles, net | 1,462,894 |  |  | 4,553 |  |  | — |  |  | 1,458,341 |
Other long-term assets | 717,301 |  |  | 82,477 |  |  | 2,946 |  |  | 631,878 |
Goodwill | 9,889,791 |  |  | 29,865 |  |  | — |  |  | 9,859,926 |
Total assets | $ | 19,341,784 |  |  | $ | 454,978 |  |  | $ | 2,946 |  |  | $ | 18,883,860 |
Current liabilities | $ | 2,773,325 |  |  | $ | 178,259 |  |  | $ | — |  |  | $ | 2,595,066 |
Payables to parent | — |  |  | 114,038 |  |  | 2,946 |  |  | (116,984 | )
Long-term debt and other long-term liabilities | 10,286,859 |  |  | 55,870 |  |  | — |  |  | 10,230,989 |
Noncontrolling interests subject to put provisions | 1,009,704 |  |  | — |  |  | — |  |  | 1,009,704 |
Total DaVita Inc. shareholders’ equity | 5,084,314 |  |  | 106,811 |  |  | — |  |  | 4,977,503 |
Noncontrolling interests not subject to put provisions | 187,582 |  |  | — |  |  | — |  |  | 187,582 |
Shareholders’ equity | 5,271,896 |  |  | 106,811 |  |  | — |  |  | 5,165,085 |
Total liabilities and shareholder’s equity | $ | 19,341,784 |  |  | $ | 454,978 |  |  | $ | 2,946 |  |  | $ | 18,883,860 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.
Condensed Consolidating Statements of Cash Flows
| Consolidated Total |  | Physician Groups |  | Unrestricted Subsidiaries |  | Company and Restricted Subsidiaries(1)
For The Six Months Ended June 30, 2017 |  |  |
Cash flows from operating activities: |  |  |  |  |  |  |
Net income | $ | 661,910 |  |  | $ | 2,000 |  |  | $ | 139 |  |  | $ | 659,771 |
Changes in operating and intercompany assets and liabilities and non-cash items included in net income | 349,534 |  |  | (37,812 | ) |  | (139 | ) |  | 387,485 |
Net cash provided by (used in) operating activities | 1,011,444 |  |  | (35,812 | ) |  | — |  |  | 1,047,256 |
Cash flows from investing activities: |  |  |  |  |  |  |  |  |  |  |
Additions of property and equipment | (398,940 | ) |  | (5,603 | ) |  | — |  |  | (393,337 | )
Acquisitions and divestitures, net | (619,839 | ) |  | — |  |  | — |  |  | (619,839 | )
Proceeds from discontinued operations | 70,236 |  |  | — |  |  | — |  |  | 70,236 |
Investments and other items | 96,895 |  |  | (1,386 | ) |  | — |  |  | 98,281 |
Net cash used in investing activities | (851,648 | ) |  | (6,989 | ) |  | — |  |  | (844,659 | )
Cash flows from financing activities: |  |  |  |  |  |  |  |  |  |  |
Long-term debt | (64,032 | ) |  | — |  |  | — |  |  | (64,032 | )
Intercompany | — |  |  | 45,342 |  |  | — |  |  | (45,342 | )
Other items | (301,146 | ) |  | — |  |  | — |  |  | (301,146 | )
Net cash (used in) provided by financing activities | (365,178 | ) |  | 45,342 |  |  | — |  |  | (410,520 | )
Effect of exchange rate changes on cash | 4,192 |  |  | — |  |  | — |  |  | 4,192 |
Net (decrease) increase in cash | (201,190 | ) |  | 2,541 |  |  | — |  |  | (203,731 | )
Cash and cash equivalents at beginning of period | 913,187 |  |  | 104,691 |  |  | — |  |  | 808,496 |
Cash and cash equivalents at end of period | $ | 711,997 |  |  | $ | 107,232 |  |  | $ | — |  |  | $ | 604,765 |
(1) | After elimination of the unrestricted subsidiaries and the physician groups.

X
- Definition The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement. + References No definition available. + Details
Name: | us-gaap_AdditionalFinancialInformationDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration